4th World Congress on Precision and Personalized Medicine

4th World Congress on Precision and Personalized Medicine

November 27 – 28 | Zurich, Switzerland

This global meeting will convene researchers, clinicians, policymakers, and industry leaders to advance innovation in precision and personalized healthcare. With the theme “Precision Medicine: Pioneering Healthcare Breakthroughs for a Healthier Future,” the program spans genomics, pharmacogenomics, biomarkers, targeted therapies, AI, digital health, and clinical implementation. Attendees can expect cutting-edge science, workshops, exhibitions, and networking focused on translating discoveries into transformative patient care.

To learn more, visit the conference webpage. Please note: Registration is required.

8th ESPT Congress

8th European Society of Pharmacogenomics and Personalized Therapy Congress

November 5 – 8 | Rotterdam, The Netherlands

ESPT 2025 will convene global experts across research, healthcare, regulation, and industry to advance pharmacogenomics and personalized therapy. The four-day program features 40+ world-class speakers, symposia, workshops, poster sessions, and discussions on topics including clinical implementation, oncology, psychiatry, cardiology, pediatrics, and regulatory aspects—providing a comprehensive look at current progress and future directions in the field.

To learn more, visit the conference webpage. Please note: Registration is required.

Rationale and design for a pragmatic randomized trial to assess gene-based prescribing for SSRIs in the treatment of depression

Posted on by Alison Kilborn

Hines LJ, Wilke RA, Myers R, Mathews CA, Liu M, Baye JF, Petry N, Cicali EJ, Duong BQ, Elwood E, Hulvershorn L, Nguyen K, Ramos M, Sadeghpour A, Wu RR, Williamson L, Wiisanen K, Voora D, Singh R, Blake KV, Murrough JW, Volpi S, Ginsburg GS, Horowitz CR, Orlando L, Chakraborty H, Dexter P, Johnson JA, Skaar TC, Cavallari LH, Van Driest SL, Peterson JF

  • DOI: 10.1111/cts.13822

An Introductory Tutorial on Cardiovascular Pharmacogenetics for Healthcare Providers

Posted on by Alexis

Akinyemi Oni-Orisan, Sony Tuteja, Glenda Hoffecker, D Max Smith, Matteo Castrichini, Kristine R Crews, William A Murphy, Nam H K Nguyen, Yimei Huang, Christelle Lteif, Kevin A Friede, Kelan Tantisira, Folefac Aminkeng, Deepak Voora, Larisa H Cavallari, Michelle Whirl-Carrillo, Julio D Duarte, Jasmine A Luzum; Pharmacogenomics Global Research Network (PGRN) Publications Committee

Clinician adherence to pharmacogenomics prescribing recommendations in clinical decision support alerts

Posted on by Alexis

Jenny Q Nguyen, Kristine R Crews, Ben T Moore, Nancy M Kornegay, Donald K Baker, Murad Hasan, Patrick K Campbell, Shannon M Dean, Mary V Relling , James M Hoffman, Cyrine E Haidar

Abstract

Thoughtful integration of interruptive clinical decision support (CDS) alerts within the electronic health record is essential to guide clinicians on the application of pharmacogenomic results at point of care. St. Jude Children’s Research Hospital implemented a preemptive pharmacogenomic testing program in 2011 in a multidisciplinary effort involving extensive education to clinicians about pharmacogenomic implications. We conducted a retrospective analysis of clinicians’ adherence to 4783 pharmacogenomically guided CDS alerts that triggered for 12 genes and 60 drugs. Clinicians adhered to the therapeutic recommendations provided in 4392 alerts (92%). In our population of pediatric patients with catastrophic illnesses, the most frequently presented gene/drug CDS alerts were TPMT/NUDT15 and thiopurines (n = 3850), CYP2D6 and ondansetron (n = 667), CYP2D6 and oxycodone (n = 99), G6PD and G6PD high-risk medications (n = 51), and CYP2C19 and proton pump inhibitors (omeprazole and pantoprazole; n = 50). The high adherence rate was facilitated by our team approach to prescribing and our collaborative CDS design and delivery.

Keywords: clinical decision support; medication alert systems; pharmacogenetics; pharmacogenomics; precision medicine.

Evidence Regarding Pharmacogenetics in Pain Management and Cancer

Posted on by Alexis

D Max Smith, William D Figg

Abstract

Patients experience interindividual variation in response to analgesics, which may be partially explained by genetics. This commentary discusses a recently published trial on COMT genotype and opioid dose requirements and describes the potential role for COMT and other genes (eg, CYP2D6) on opioid therapy and the current evidence for germline pharmacogenetics and resources for opioid pharmacogenetics.

Keywords: cancer pain; opioids; pain; pharmacogenetics; pharmacogenomics.